Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is expected to reach US$ 29.87 Bn. at a CAGR of 5.5% during the forecast period 2029. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region.To know about the Research Methodology :- Request Free Sample Report Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. Tobacco smoking is the most common cause of COPD, with factors such as air pollution and genetics. There are several lifestyle-related factors such as smoking, exposure to biomass fuel, and air pollution, which increase the risk of developing COPD. In addition to tobacco smoke, there are other factors such as occupational exposure, outdoor pollution. Exposure to second-hand or passive smoking. Smoke from the burning of biomass, respiratory infections, poor nutritional status, chronic asthma, impaired lung growth, poor socio-economic status and dietary factors, which lead directly or indirectly to COPD. Increasing preference of pulmonary route as an alternate route of drug delivery, rising focus on the development of smart/digital inhalers and incidence of respiratory diseases i.e., asthma, and cystic fibrosis is expected to drive the market growth during the forecast period. However, emerging markets and growth in online marketing channel offers opportunities for the market. New drug development by market players through collaborations and increase in research and development expenditure are anticipated to drive the global market. Propeller Health and Novartis Pharma AG entered into collaboration to develop a custom add-on sensor for the Breezhaler inhaler, a device indicated for COPD treatments. Rise in number of public and private organizations is another major factor propelling the growth of COPD Treatment market. For instance, organizations such as the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) are engaged in providing information in clinical and basic research on allergy, asthma, and clinical immunology. Such initiatives are in turn expected to increase the market in developing regions, thereby boosting overall market growth. There is a lack of knowledge and awareness about COPD especially in the developing countries due to which primary care practitioners (PCPs) and other healthcare providers delay or incorrectly diagnose COPD. Another major factor contributing to the poor diagnosis of COPD is the diagnostic confusion between COPD and asthma. Thus, poor or incorrect diagnosis is a major challenge as it prevents people with COPD from getting a proper diagnosis which, in turn, has a negative impact on market growth. By drug type, bronchodilators are further categorized as Short-Acting Bronchodilators and Long- Acting Bronchodilators. These medications work quickly to relax the muscles around your airways and ease symptoms like coughing and shortness of breath. The effects last for about 6 to 12 hours. North America dominates Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market because of rise in collaborations and high investments in healthcare sector. Globally the market for COPD is increasing rapidly. The major factor that derives the growth of COPD is the increasing growth in smoking in adults. The objective of the report is to present comprehensive analysis of Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding dynamics, structure by analyzing the market segments, and project the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market size. Clear representation of competitive analysis of key players by Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market make the report investor’s guide.
Chronic Obstructive Pulmonary Disease (COPD) Treatment market Scope : Inquire before buying
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 20.53 Bn. Forecast Period 2023 to 2029 CAGR: 5.5% Market Size in 2029: US $ 29.87 Bn. Segments Covered: by Product combination, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitors, mucokineticsm by Type hospital pharmacies, retail pharmacies, online pharmacies. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Key players
1. AstraZeneca, 2. Boehringer Ingelheim Pharmaceuticals, Inc., 3. GlaxoSmithKline plc, 4. Novartis AG, 5. CHIESI Farmaceutici S.p.A., 6. Sunovion Pharmaceuticals, Inc. 7. Teva Pharmaceutical Industries Ltd, 8. Mylan N.V. 9. Orion Corporation. 10.Abbott 11.Dr. Reddy's Laboratories Ltd 12.F. Hoffmann-La Roche Ltd 13.Forest Labs 14.GSK 15.Galapagos NV 16.Merck 17.Mundipharma 18.Nycomed 19.Orexo 20.Pfizer Inc 21.Roche 22.Almirall 23.Astellas Pharma 24.Circassia Pharmaceuticals Frequently Asked Questions: 1. Which region has the largest share in Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market? Ans: North America region holds the highest share in 2022. 2. What is the growth rate of Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market? Ans: The Global Market is growing at a CAGR of 5.5% during forecasting period 2023-2029. 3. What is scope of the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment market report? Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global market? Ans: The important key players in the Global Market are – AstraZeneca,, Boehringer Ingelheim Pharmaceuticals, Inc.,, GlaxoSmithKline plc,, Novartis AG,, CHIESI Farmaceutici S.p.A.,, Sunovion Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd,, Mylan N.V., Orion Corporation., Abbott, Dr. Reddy's Laboratories Ltd, F. Hoffmann-La Roche Ltd, Forest Labs, GSK, Galapagos NV, Merck, Mundipharma, Nycomed, Orexo, Pfizer Inc, Roche, Almirall, Astellas Pharma, and Circassia Pharmaceuticals 5. What is the study period of this market? Ans: The Global Market is studied from 2022 to 2029.
1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Dynamics 2.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Trends by Region 2.1.1. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Trends 2.1.2. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Trends 2.1.3. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Trends 2.1.4. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Trends 2.1.5. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Trends 2.2. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Drivers 2.2.1.2. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Restraints 2.2.1.3. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Opportunities 2.2.1.4. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Challenges 2.2.2. Europe 2.2.2.1. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Drivers 2.2.2.2. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Restraints 2.2.2.3. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Opportunities 2.2.2.4. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Drivers 2.2.3.2. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Restraints 2.2.3.3. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Opportunities 2.2.3.4. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Drivers 2.2.4.2. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Restraints 2.2.4.3. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Opportunities 2.2.4.4. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Challenges 2.2.5. South America 2.2.5.1. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Drivers 2.2.5.2. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Restraints 2.2.5.3. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Opportunities 2.2.5.4. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Chronic Obstructive Pulmonary Disease (COPD) Treatment Industry 2.8. Analysis of Government Schemes and Initiatives For Chronic Obstructive Pulmonary Disease (COPD) Treatment Industry 2.9. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Trade Analysis 2.10. The Global Pandemic Impact on Chronic Obstructive Pulmonary Disease (COPD) Treatment Market 3. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2022-2029 3.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 3.1.1. combination, 3.1.2. bronchodilators, 3.1.3. corticosteroids, 3.1.4. phosphodiesterase type 4 inhibitors, 3.1.5. mucokineticsm 3.2. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 3.2.1. pharmacies, 3.2.2. retail pharmacies, 3.2.3. online pharmacies. 3.3. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Region (2022-2029) 3.3.1. North America 3.3.2. Europe 3.3.3. Asia Pacific 3.3.4. Middle East and Africa 3.3.5. South America 4. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 4.1. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 4.1.1. combination, 4.1.2. bronchodilators, 4.1.3. corticosteroids, 4.1.4. phosphodiesterase type 4 inhibitors, 4.1.5. mucokineticsm 4.2. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 4.2.1. pharmacies, 4.2.2. retail pharmacies, 4.2.3. online pharmacies. 4.3. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Country (2022-2029) 4.3.1. United States 4.3.1.1. United States Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 4.3.1.1.1. combination, 4.3.1.1.2. bronchodilators, 4.3.1.1.3. corticosteroids, 4.3.1.1.4. phosphodiesterase type 4 inhibitors, 4.3.1.1.5. mucokineticsm 4.3.1.2. United States Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 4.3.1.2.1. pharmacies, 4.3.1.2.2. retail pharmacies, 4.3.1.2.3. online pharmacies. 4.3.2. Canada 4.3.2.1. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 4.3.2.1.1. combination, 4.3.2.1.2. bronchodilators, 4.3.2.1.3. corticosteroids, 4.3.2.1.4. phosphodiesterase type 4 inhibitors, 4.3.2.1.5. mucokineticsm 4.3.2.2. Canada Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 4.3.2.2.1. pharmacies, 4.3.2.2.2. retail pharmacies, 4.3.2.2.3. online pharmacies. 4.3.3. Mexico 4.3.3.1. Mexico Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 4.3.3.1.1. combination, 4.3.3.1.2. bronchodilators, 4.3.3.1.3. corticosteroids, 4.3.3.1.4. phosphodiesterase type 4 inhibitors, 4.3.3.1.5. mucokineticsm 4.3.3.2. Mexico Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 4.3.3.2.1. pharmacies, 4.3.3.2.2. retail pharmacies, 4.3.3.2.3. online pharmacies. 5. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 5.1. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 5.2. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 5.3. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Country (2022-2029) 5.3.1. United Kingdom 5.3.1.1. United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 5.3.1.2. United Kingdom Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 5.3.2. France 5.3.2.1. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 5.3.2.2. France Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 5.3.3. Germany 5.3.3.1. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 5.3.3.2. Germany Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 5.3.4. Italy 5.3.4.1. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 5.3.4.2. Italy Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 5.3.5. Spain 5.3.5.1. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 5.3.5.2. Spain Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 5.3.6. Sweden 5.3.6.1. Sweden Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 5.3.6.2. Sweden Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 5.3.7. Austria 5.3.7.1. Austria Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 5.3.7.2. Austria Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 5.3.8. Rest of Europe 5.3.8.1. Rest of Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 5.3.8.2. Rest of Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 6. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 6.1. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 6.2. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 6.3. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Country (2022-2029) 6.3.1. China 6.3.1.1. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 6.3.1.2. China Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 6.3.2. S Korea 6.3.2.1. S Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 6.3.2.2. S Korea Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 6.3.3. Japan 6.3.3.1. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 6.3.3.2. Japan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 6.3.4. India 6.3.4.1. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 6.3.4.2. India Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 6.3.5. Australia 6.3.5.1. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 6.3.5.2. Australia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 6.3.6. Indonesia 6.3.6.1. Indonesia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 6.3.6.2. Indonesia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 6.3.7. Malaysia 6.3.7.1. Malaysia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 6.3.7.2. Malaysia Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 6.3.8. Vietnam 6.3.8.1. Vietnam Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 6.3.8.2. Vietnam Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 6.3.9. Taiwan 6.3.9.1. Taiwan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 6.3.9.2. Taiwan Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 6.3.10. Rest of Asia Pacific 6.3.10.1. Rest of Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 6.3.10.2. Rest of Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 7. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 7.1. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 7.2. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 7.3. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Country (2022-2029) 7.3.1. South Africa 7.3.1.1. South Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 7.3.1.2. South Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 7.3.2. GCC 7.3.2.1. GCC Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 7.3.2.2. GCC Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 7.3.3. Nigeria 7.3.3.1. Nigeria Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 7.3.3.2. Nigeria Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 7.3.4. Rest of ME&A 7.3.4.1. Rest of ME&A Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 7.3.4.2. Rest of ME&A Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 8. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 8.1. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 8.2. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 8.3. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Country (2022-2029) 8.3.1. Brazil 8.3.1.1. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 8.3.1.2. Brazil Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 8.3.2. Argentina 8.3.2.1. Argentina Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 8.3.2.2. Argentina Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 8.3.3. Rest Of South America 8.3.3.1. Rest Of South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Product (2022-2029) 8.3.3.2. Rest Of South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size and Forecast, by Type hospital (2022-2029) 9. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. AstraZeneca, 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Boehringer Ingelheim Pharmaceuticals, Inc., 10.3. GlaxoSmithKline plc, 10.4. Novartis AG, 10.5. CHIESI Farmaceutici S.p.A., 10.6. Sunovion Pharmaceuticals, Inc. 10.7. Teva Pharmaceutical Industries Ltd, 10.8. Mylan N.V. 10.9. Orion Corporation. 10.10. Abbott 10.11. Dr. Reddy's Laboratories Ltd 10.12. F. Hoffmann-La Roche Ltd 10.13. Forest Labs 10.14. GSK 10.15. Galapagos NV 10.16. Merck 10.17. Mundipharma 10.18. Nycomed 10.19. Orexo 10.20. Pfizer Inc 10.21. Roche 10.22. Almirall 10.23. Astellas Pharma 10.24. Circassia Pharmaceuticals 11. Key Findings 12. Industry Recommendations 13. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Research Methodology 14. Terms and Glossary